Clinical trials: Oral Phase
Obesity, Overweight
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.
- Trial name
- EVOLVE-2 (NCT07281937)
- Testing
- VRB-101
- Where
- 22 sites in United States
- Volunteers
- 206 people
- Sponsor
- Verdiva Bio Dev Limited
Gingivitis
Dose-Response Study of Iocide Oral Rinse
The purpose of this study is to explore the dose-response relationship of Iocide oral rinse in a clinical trial of gingivitis. Approximately sixty (60) otherwise healthy subjects having gingivitis will be randomized into the…
- Trial name
- NCT01103102
- Testing
- Iocide Oral Rinse
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Biomedical Development Corporation
Overweight or Obesity
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）
This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study to evaluate the efficacy and safety of the oral small molecule MDR-001 Tablets over 52 weeks as an adjunct to a lifestyle intervention…
- Trial name
- NCT07274137
- Testing
- MDR-001
- Where
- 45 sites in China
- Volunteers
- 738 people
- Sponsor
- MindRank AI Ltd
Advanced Solid Tumor, Liver Metastases
Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases
Single centre recruiting approximately 80 patients who are given a rising single, followed by multiple, ascending oral dose of AZD2171, assessing the safety and tolerability of AZD2171 in patients with solid tumors and metastatic…
- Trial name
- NCT00501605
- Testing
- AZD2171
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
Neoplasms
Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours
The primary objective of the study was to identify the maximum tolerated dose and to evaluate safety, pharmacokinetics, pharmacodynamic parameters, and efficacy of BIBW 2992.
- Trial name
- NCT02171702
- Testing
- BIBW 2992
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Dental Caries
Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects
The purpose of the clinical study is to evaluate the safety and bacterial impact of study drug (C16G2) administered in multiple oral gel doses to adolescent and adult dental subjects.
- Trial name
- NCT02509845
- Testing
- C16G2
- Where
- 5 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Armata Pharmaceuticals, Inc.
Solid Tumours
To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours
This is a 3-part study in patients with advanced solid tumours: Part A will assess the effect of itraconazole on the PK parameters of olaparib and will determine the effect of olaparib on the QT interval following single oral…
- Trial name
- NCT01900028
- Testing
- Pharmacokinetic sampling, Olaparib tablet dosing, Itraconazole
- Where
- 14 sites in Belgium, Denmark and 2 more
- Volunteers
- 85 people
- Sponsor
- AstraZeneca
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of TY-1091 in Patients With Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of TY-1091 administered orally in…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, Neoplasms
- Trial name
- NCT05675605
- Testing
- TY-1091
- Where
- China
- Volunteers
- 248 people
- Sponsor
- TYK Medicines, Inc
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in Healthy Subjects
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple repeat oral doses of PF-06372865 in healthy adult subjects.
- Trial name
- NCT03351751
- Testing
- PF-06372865
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Subject
A Study of ALS-4 in Healthy Adults Subjects
A Phase I trial to evaluate the safety, tolerability and Pharmacokinetics of ALS-4 (IM032) in a single ascending dose (SAD) and multiple ascending dose (MAD) in healthy adult subjects.
- Trial name
- NCT05274802
- Testing
- ALS-4
- Where
- Canada
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Aptorum International Limited
Healthy Participants
Mass Balance Clinical Trial With TEV-56286
Mass balance clinical trial with TEV-56286
- Trial name
- NCT06627231
- Testing
- TEV-56286, [14C]-TEV-56286
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Solid Tumors, Cancer
Trial of MSC1936369B in Subjects With Solid Tumors
This is a first in man trial with a primary objective being the determination of the Maximum Tolerated dose (MTD) and the dose-limiting toxicity (DLT) in several regimens of MEK inhibitor MSC1936369B administered orally once a…
- Trial name
- NCT00982865
- Testing
- MSC1936369B
- Where
- 9 sites in Australia, Belgium and 2 more
- Volunteers
- 182 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Ovarian Cancer, Triple-negative Breast Cancer
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
This is an open label, Phase 1b/2 study with multiple treatment arms evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of rucaparib in combination with a second anticancer therapy in…
- Conditions
- Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma, Solid Tumor
- Trial name
- NCT03992131
- Testing
- Rucaparib, Lucitanib, Sacituzumab govitecan
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- pharmaand GmbH
Healthy
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers
To investigate the safety, tolerability, and pharmacokinetics incl. dose proportionality of BI 113823, as well as the relative bioavailability of PiB vs. tablet and tablet fasted vs. fed (food effect for the tablet).
- Trial name
- NCT02259972
- Testing
- BI 113823 solution, BI 113823 tablet, High fat, high calorie breakfast
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Acne Vulgaris
Efficacy And Safety Of Azithromycin SR Compared With Minocycline In Acne
The primary objective is to evaluate the clinical efficacy of azithromycin microspheres treatment in outpatients with moderate to severe inflammatory acne compared with first line treatment minocycline after 8 weeks of therapy
- Trial name
- NCT00392223
- Testing
- Azithromycin microspheres, Minocycline capsules,
- Where
- 17 sites in Italy
- Volunteers
- 118 people
- Sponsor
- Pfizer
Healthy Volunteers
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential
This is an open-label, single-center, two part study in healthy female subjects of non-childbearing potential to investigate the absorption, metabolism, and excretion of [14C]-GDC-9545 (Part 1), the absolute bioavailability of…
- Trial name
- NCT04680273
- Testing
- [14C]-GDC-9545, GDC-9545 Solution for Infusion, GDC-9545/F12 Capsule
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Gastroesophageal Reflux Disease (GERD)
Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD)…
- Trial name
- NCT03561883
- Testing
- IW-3718, Standard-dose PPIs QD
- Where
- 101 sites in United States, Canada
- Volunteers
- 609 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Hyperlipidemia
Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at various lipids in the blood of people with Fredrickson Type IIa and Type IIb mixed dyslipidemias
- Trial name
- NCT00137462
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 59 sites in United States, Canada
- Volunteers
- 900 people
- Sponsor
- Pfizer
Obesity &Amp; Overweight
Phase Ib Clinical Study on the Efficacy and Safety of MDR-001 in Patients Who Are Obesity or Overweight
This is a 12 weeks, multicenter, randomized, double-blind, placebo, parallel-controlled Phase Ib trail comparing the efficacy and safety of MDR-001 tablet versus placebo as an adjunct to a reduced calorie diet and increased…
- Trial name
- NCT07110766
- Testing
- MDR-001
- Where
- China
- Volunteers
- 24 people
- Sponsor
- MindRank AI Ltd
Atopic Dermatitis
A Clinical Study of HRS-8797 in Healthy Participants
The purpose of this phase I study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-8797 in healthy participants.
- Trial name
- NCT07698756
- Testing
- HRS-8797
- Where
- China
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.